Half-life
~5–6 days
SKUs Available
1
Evidence Level
Moderate Evidence
Mechanism of Action
Dual GLP-1 and glucagon receptor agonism. Glucagon component may enhance fatty acid oxidation and thermogenesis.
Published Research Ranges & Study Context
Studies have administered: 0.6–6mg weekly in phase 2 studies
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
SYNCHRONIZE-1 trial investigating NASH/metabolic dysfunction. Phase 2 data showed significant liver fat reduction.
Moderate Evidence
Phase 1/2 human trials available
Side Effects Observed in Research
GI symptoms consistent with GLP-1 class; some liver enzyme elevations monitored in trials
Available Configurations (SKU Reference)
SUR10
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Survodutide — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.